Janux Therapeutics has dosed the first patient at the City of Hope, US, in a Phase I trial of JANX008, designed to treat patients with advanced or metastatic solid tumours.
JANX008 will be evaluated in patients with these tumours, and including colorectal cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and renal cell carcinoma.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open-label, multicentre dose escalation and dose expansion study will investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of JANX008.
It will assess the preliminary anti-tumour activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing epidermal growth factor receptor (EGFR).
Janux CEO and president David Campbell said: “JANX008 is the second therapeutic from our TRACTr platform to enter a first-in-human clinical trial, demonstrating the potential of our platform and the commitment of our team to address critical and urgent unmet needs for patients with advanced or metastatic solid tumours.”
An EGFR-directed T cell engager (TCE), JANX008 uses the company’s TRACTr platform to be administered in humans.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataJanux chief medical officer Wayne Godfrey said: “JANX008 is designed to achieve tumour-selective T cell activation and tumour killing while sparing healthy tissues.
“Our preclinical data with JANX008 demonstrated tumour growth inhibition and lower toxicity levels when compared to an unmasked T cell engager.”
